• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

NPJ Aging . Severe COVID-19 patients exhibit elevated levels of autoantibodies targeting cardiolipin and platelet glycoprotein with age: a systems

tetano

Editor, Senior Moderator
NPJ Aging


. 2023 Aug 24;9(1):21.
doi: 10.1038/s41514-023-00118-0. Severe COVID-19 patients exhibit elevated levels of autoantibodies targeting cardiolipin and platelet glycoprotein with age: a systems biology approach

Dennyson Leandro M Fonseca[SUP] #[/SUP][SUP] 1 [/SUP], Igor Salerno Filgueiras[SUP] #[/SUP][SUP] 2 [/SUP], Alexandre H C Marques[SUP] 2 [/SUP], Elroy Vojdani[SUP] 3 [/SUP], Gilad Halpert[SUP] 4 5 6 [/SUP], Yuri Ostrinski[SUP] 4 5 6 [/SUP], Gabriela Crispim Baiocchi[SUP] 2 [/SUP], Desirée Rodrigues Plaça[SUP] 7 [/SUP], Paula P Freire[SUP] 2 [/SUP], Shahab Zaki Pour[SUP] 8 [/SUP], Guido Moll[SUP] 9 [/SUP], Rusan Catar[SUP] 9 [/SUP], Yael Bublil Lavi[SUP] 10 [/SUP], Jonathan I Silverberg[SUP] 11 [/SUP], Jason Zimmerman[SUP] 12 [/SUP], Gustavo Cabral-Miranda[SUP] 2 [/SUP], Robson F Carvalho[SUP] 13 [/SUP], Taj Ali Khan[SUP] 14 [/SUP], Harald Heidecke[SUP] 15 [/SUP], Rodrigo J S Dalmolin[SUP] 16 17 [/SUP], Andre Ducati Luchessi[SUP] 18 [/SUP], Hans D Ochs[SUP] 19 [/SUP], Lena F Schimke[SUP] 2 [/SUP], Howard Amital[SUP] 4 5 20 21 [/SUP], Gabriela Riemekasten[SUP] 22 [/SUP], Israel Zyskind[SUP] #[/SUP][SUP] 12 23 [/SUP], Avi Z Rosenberg[SUP] #[/SUP][SUP] 24 [/SUP], Aristo Vojdani[SUP] #[/SUP][SUP] 25 26 [/SUP], Yehuda Shoenfeld[SUP] #[/SUP][SUP] 5 [/SUP], Otavio Cabral-Marques[SUP] #[/SUP][SUP] 27 28 29 30 31 32 33 [/SUP]



Affiliations
Abstract

Age is a significant risk factor for the coronavirus disease 2019 (COVID-19) severity due to immunosenescence and certain age-dependent medical conditions (e.g., obesity, cardiovascular disorder, and chronic respiratory disease). However, despite the well-known influence of age on autoantibody biology in health and disease, its impact on the risk of developing severe COVID-19 remains poorly explored. Here, we performed a cross-sectional study of autoantibodies directed against 58 targets associated with autoimmune diseases in 159 individuals with different COVID-19 severity (71 mild, 61 moderate, and 27 with severe symptoms) and 73 healthy controls. We found that the natural production of autoantibodies increases with age and is exacerbated by SARS-CoV-2 infection, mostly in severe COVID-19 patients. Multiple linear regression analysis showed that severe COVID-19 patients have a significant age-associated increase of autoantibody levels against 16 targets (e.g., amyloid β peptide, β catenin, cardiolipin, claudin, enteric nerve, fibulin, insulin receptor a, and platelet glycoprotein). Principal component analysis with spectrum decomposition and hierarchical clustering analysis based on these autoantibodies indicated an age-dependent stratification of severe COVID-19 patients. Random forest analysis ranked autoantibodies targeting cardiolipin, claudin, and platelet glycoprotein as the three most crucial autoantibodies for the stratification of severe COVID-19 patients ≥50 years of age. Follow-up analysis using binomial logistic regression found that anti-cardiolipin and anti-platelet glycoprotein autoantibodies significantly increased the likelihood of developing a severe COVID-19 phenotype with aging. These findings provide key insights to explain why aging increases the chance of developing more severe COVID-19 phenotypes.


 
Back
Top Bottom